These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 21851796

  • 1. How to improve the clinical development paradigm and its division into phases I, II and III.
    Bamberger M, Moore N, Lechat P, participants of Round Table N° 3 of Giens XXVI.
    Therapie; 2011; 66(4):331-4, 327-30. PubMed ID: 21851796
    [Abstract] [Full Text] [Related]

  • 2. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J, Puech A, Boissel JP, Participants inRound Table No 7, Giens XXII.
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [Abstract] [Full Text] [Related]

  • 3. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE, Kleijnen J.
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Lessons learned from independent central review.
    Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J.
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Difficulties with conducting clinical trials in France].
    Zannad F, Plétan Y.
    Therapie; 2001 Jan; 56(4):341-7. PubMed ID: 11677850
    [Abstract] [Full Text] [Related]

  • 10. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S, Sucić AF, Martinac AI.
    Regul Toxicol Pharmacol; 2010 Jan; 57(2-3):325-32. PubMed ID: 20385190
    [Abstract] [Full Text] [Related]

  • 11. Standardization, more funds on horizon for clinical trials.
    McNeil C.
    J Natl Cancer Inst; 2005 Apr 20; 97(8):555-7. PubMed ID: 15840874
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A, Felisi M, Catapano M, Baiardi P, Cipollina L, Ravera S, Bagnulo S, Reggio S, Rondini G.
    Eur J Clin Pharmacol; 2002 Nov 20; 58(8):495-500. PubMed ID: 12451425
    [Abstract] [Full Text] [Related]

  • 15. Drug research: from the idea to the product.
    Kuhlmann J.
    Int J Clin Pharmacol Ther; 1997 Dec 20; 35(12):541-52. PubMed ID: 9455711
    [Abstract] [Full Text] [Related]

  • 16. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec 20; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.